Revised diagnostic criteria for myeloid neoplasms (MN) issued by the International
Consensus Classification (ICC) and the World Health Organization (WHO) recommended …

TP53 is a tumor suppressor gene frequently mutated in human cancers and is generally
associated with poor outcomes. TP53 mutations are found in approximately 5% to 10% of …

Therapy-related myeloid neoplasm (t-MN), characterized by its association with prior
exposure to cytotoxic therapy, remains poorly understood and is a major impediment to long …

Chronic myelomonocytic leukemia (CMML) is a myelodysplastic/myeloproliferative overlap
neoplasm characterized by sustained peripheral blood (PB) absolute (≥ 0.5× 109/l) and …

Rare preleukemic hematopoietic stem cells (pHSC) harboring only the initiating mutations
can be detected at the time of acute myeloid leukemia (AML) diagnosis. pHSCs are the …

Therapy-related myeloid neoplasms (t-MN) are a growing concern due to the continued use
of cytotoxic therapies to treat malignancies. Cytotoxic therapies have been shown to drive …

Therapy-related myeloid neoplasms (t-MN) are aggressive myeloid neoplasms. Factors
predicting post-allogeneic stem cell transplant (alloSCT) survival are not well-known. We …

While there is clear evidence to suggest poorer outcome associated with multi-hit (MH) TP53
mutation (TP53MT) compared to a single-hit (SH) mutation in lower-risk myelodysplastic …

Upfront autologous stem cell transplant (ASCT) is the standard of care for newly diagnosed
multiple myeloma (MM) patients. However, relapse is ubiquitous and therapy-related …

Simple Summary Myelodysplastic syndrome (MDS) is one of the most-common blood
cancers in older individuals. Although azacitidine is the most-commonly used treatment for …